LUNG HEALTH STUDY--LONG TERM FOLLOW UP
Principal Investigator: Donald Tashkin
Abstract: The Lung Health Study (LHS), conducted from 1986-1994, demonstrated that a smoking intervention program in middle-aged long-term cigarette smokers can result in a highly significant beneficial effect on the rate of FEV1 decline over five years. However, FEV1 is only a surrogate marker for clinical outcomes of respiratory morbidity and mortality. The present study proposes long-term post-trial follow-up of former LHS participants to assess the incidence of morbidity and mortality from respiratory and cardiovascular diseases and other causes, as documented by hospital, clinic, and death records. A pulmonary function test 11 to 12 years after entry into the LHS is also proposed to determine long- term effects of the LHS smoking intervention program on lung function. The main objectives of the study are as follows: 1) to determine, using an intent-to-treat analysis, whether the LHS smoking intervention significantly reduces the incidence of clinically important respiratory and cardiovascular disease over a 12- to 15-year period following study enrollment; 2) to determine whether the beneficial effect of the smoking intervention program on measures of lung function persists through 11 to 12 years of follow-up; 3) to estimate the magnitude of the effects of FEV1 and FVC on the risks of cardiovascular and respiratory morbidity and mortality, after controlling for smoking history; 4) to study the role of other factors [gender, airways reactivity, weight gain, and co- morbidities] in determining the rate of decline in pulmonary function and the risks of cardiovascular and respiratory morbidity and mortality. All ten of the original LHS clinical centers plan to participate in this study. To minimize bias, all surviving participants of the LHS will be invited to participate, giving a potential sample size of 5600.
Funding Period: 1998-02-01 - 2003-01-31
more information: NIH RePORT
- High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung diseaseJonathan G Goldin
David Geffen School of Medicine at UCLA, Department of Radiology, Los Angeles, CA 90095 1721, USA
Chest 134:358-67. 2008..The frequency, nature, and progression of interstitial lung disease seen on high-resolution CT (HRCT) scans in patients with diffuse SSc (dcSSc) compared with those with limited SSc (lcSSc) has not been well characterized...
- Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD?S F P Man
The James Hogg iCAPTURE Center for Cardiovascular and Pulmonary Research, St Paul s Hospital, Vancouver, BC, Canada
Eur Respir J 32:1451-7. 2008..While promising, future studies are needed to validate this simple index as a biomarker in COPD...